Kenya's Oncology Fund Covers Chemotherapy but Not the Pathology That Guides It
Kenya's public oncology fund pays for chemotherapy drugs and radiotherapy sessions but not, in most cases, for the biopsy and laboratory work that tells clinicians which of those drugs a patient actually needs. The result is a coverage design that funds treatment while leaving diagnosis to the patient's own pocket.
The Coverage Gap in Kenyan Cancer Care
Kenya's National Health Insurance Fund has, since 2017, operated a dedicated oncology benefit that covers chemotherapy and radiotherapy for enrolled members. The benefit package lists drugs and radiation fractions. It does not list the tissue diagnosis that determines whether a patient should receive those drugs at all.
That omission matters because cancer treatment is not one thing. A chemotherapy regimen chosen without a tissue diagnosis is chosen blind. The clinician knows a mass is present but not what kind of cells it contains, which receptor proteins those cells express, or whether a targeted drug would work better than cytotoxic chemotherapy.
Patients who cannot pay for pathology out of pocket often start treatment anyway, on the basis of imaging and clinical judgment alone. A related piece on this site described how diabetes diagnoses in Nigeria arrive after organ damage has begun; the pattern of late, incomplete diagnosis is familiar across the region.
How the Oncology Fund Works
The fund was launched in 2017 as a ring-fenced benefit within NHIF, intended to keep cancer treatment affordable for members who would otherwise face catastrophic costs. It covers chemotherapy cycles and radiotherapy sessions at accredited facilities, with the fund reimbursing hospitals on a negotiated schedule.
Pathology is not part of that schedule. A hospital that performs a biopsy and sends tissue to a laboratory must either absorb the cost or bill the patient directly. Most facilities bill the patient, because the reimbursement the hospital receives for chemotherapy does not include a margin for diagnostic work.
The design creates an incentive that runs the wrong way. A hospital is paid for treatment but not for the test that guides treatment. It is paid for the fourth cycle of a drug but not for the receptor assay that would have shown the drug was the wrong choice.
Consider the case of a 52-year-old woman in Kisumu with a breast lump. She undergoes a fine-needle aspiration at a district hospital, but the sample is inadequate for receptor testing. She is referred to a private laboratory in Nairobi, where a core biopsy and immunohistochemistry panel would cost her roughly KES 30,000 to 50,000. Her monthly income is about KES 15,000. She cannot afford the test, so she starts chemotherapy based on imaging alone. If her tumor is HER2-positive, she will miss the benefit of trastuzumab; if it is hormone receptor-positive, she may receive chemotherapy when endocrine therapy alone would suffice. This scenario is common, though precise national data on how often it occurs are lacking.
The Cost of Diagnostic Pathology
A basic biopsy in Kenya typically costs somewhere in the range of KES 10,000 to 30,000 at a private laboratory, depending on the site and the complexity of the sample. Immunohistochemistry, which stains tissue for proteins such as HER2, estrogen receptor, and progesterone receptor, adds roughly KES 15,000 to 40,000 per panel.
Those figures are out of reach for many households. Kenya's average monthly household income is far below the cost of a single immunohistochemistry panel, let alone the multiple panels a breast cancer workup may require. A patient may spend more on diagnosis than on the first cycle of chemotherapy.
Few public laboratories offer the full range of specialized stains. Most immunohistochemistry in Kenya is performed in private laboratories, concentrated in Nairobi and a handful of other urban centres. Turnaround times for a full panel can stretch from one week to several weeks, depending on the laboratory and the completeness of the request.
The result is a two-tier system. Patients who can pay get a precise diagnosis and a targeted treatment plan. Patients who cannot pay get a clinical guess and a generic regimen.
Clinical Consequences of Delayed Diagnosis
Without pathology, chemotherapy is selected on the basis of tumour size, location, and imaging appearance. That is a poor substitute for receptor status. In breast cancer, the difference between hormone receptor-positive and triple-negative disease determines whether endocrine therapy or cytotoxic chemotherapy is the appropriate backbone.
HER2-positive breast cancer is the clearest example. Patients with HER2 amplification benefit from targeted drugs such as trastuzumab, which are not effective in HER2-negative disease. Giving trastuzumab without knowing HER2 status wastes a costly drug and exposes the patient to cardiotoxicity for no benefit.
Guidelines from international oncology bodies assume a tissue diagnosis. They assume the clinician knows the subtype, the grade, and the receptor profile. When that information is absent, the guidelines cannot be applied as written. Clinicians adapt, but adaptation is not the same as evidence-based care.
The delay itself carries cost. A patient who waits weeks for a biopsy result may present at a later stage by the time treatment begins. A paper on this site noted that birth asphyxia outcomes in Kenya differ from those in DR Congo; the broader lesson is that health system performance turns on which services are funded and which are not.
Equity and Access Challenges
Rural patients face a compounded burden. The biopsy may be available at a district hospital, but the specialized staining is not. Tissue samples must be transported to Nairobi or another urban centre, adding travel, courier costs, and delay.
Kenya has a documented shortage of pathologists. The number of practising pathologists per capita is low by any regional comparison, and most are concentrated in urban referral hospitals and private practice. A public sector pathologist may read a volume of cases that would be shared among several colleagues in a higher-income country.
The fund's design favours treatment over diagnosis. Chemotherapy is visible, billable, and politically salient. A pathology result is invisible, unbillable, and easy to defer. That asymmetry explains why the benefit package looks the way it does, and why fixing it requires a deliberate policy choice rather than a nudge.
Private laboratories dominate specialized testing, which means the public system depends on private capacity it does not control. When private labs raise prices or deprioritize public sector samples, the bottleneck tightens without any public accountability mechanism.
Economic Trade-offs of Coverage Design
Adding pathology to the oncology benefit would not be free. The fund would need to negotiate reimbursement rates for biopsy and immunohistochemistry, and it would need to ensure that accredited facilities have the capacity to deliver these services. But the cost of covering a panel is far less than the cost of a single cycle of many chemotherapy regimens. For example, a course of trastuzumab can run into hundreds of thousands of shillings, while an immunohistochemistry panel costs a fraction of that. Covering the test would not only improve outcomes but also reduce spending on ineffective drugs.
There is also a question of prioritization. Kenya's health budget is finite, and every addition to the benefit package means trade-offs elsewhere. However, diagnostic pathology is not an add-on; it is the foundation of effective cancer care. Without it, the fund is paying for treatments that may be wrong. The economic case for inclusion is strong, even if the political case is harder to make.
Practical Steps for Stakeholders
Include diagnostic pathology in the NHIF oncology benefit package. The fund already pays for chemotherapy; adding biopsy and immunohistochemistry to the reimbursable schedule would shift the cost from patients to the insurer and remove the incentive to treat blind.
Expand public laboratory capacity for immunohistochemistry. Equipping regional referral hospitals with staining capability would reduce transport delays and decentralize access beyond Nairobi.
Train more pathologists through subsidized residency positions and retention incentives. The shortage is a pipeline problem, and it will not resolve without deliberate investment in training slots and public sector posts.
Subsidize immunohistochemistry for patients enrolled in the oncology fund. A targeted subsidy for receptor testing in breast cancer would cost a fraction of the chemotherapy cycles it would help direct.
Advocate for policy change through professional associations and patient groups. The benefit package is an administrative document, not a statute; it can be amended, and the amendment process is where the leverage lies.
This article is informational and does not constitute personalized medical or financial advice. Patients should consult qualified clinicians about their own diagnosis and treatment options.
